Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II

NCT: NCT02890160 · COMPLETED

NCT IDNCT02890160
StatusCOMPLETED
Start Date2017-08-24
Completion2024-10-03
SponsorShanghai MicroPort Medical (Group) Co., Ltd. (INDUSTRY)
First posted
Last updated

Brief Summary

The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑